9 results about "Radiosynthesis" patented technology

A method for preparing an 18F-labeled imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a chelating moiety, and optionally a linker. In representative aspects, the 18F-labeled imaging agent is [18F]-DK222.

A radiosynthesis system is disclosed that leverages droplet microfluidic radiosynthesis and its inherent advantages including reduction of reagent consumption and the ability to achieve high molar activity even when using low starting radioactivity. The radiosynthesis system enables the parallel synthesis of radiolabeled compounds using droplet-sized reaction volumes. In some embodiments, a single heater is used to create multiple reaction or synthesis sites. In other embodiments, separate heaters are used to create independently-controlled heating conditions at the multiple reaction or synthesis sites. In one embodiment, a four-heater setup was developed that utilizes a multi-reaction microfluidic chip and was assessed for the suitability with high-throughput radiosynthesis optimization. Replicates of several radiochemical operations including the full synthesis of various PET tracers revealed the platform to have high repeatability (e.g., consistent fluorination efficiency). The system may also be used for synthesis optimization.

The present disclosure relates to an [¹⁸F]-labeled imidazopyridine derivative or a salt thereof, as a positron emission tomography (PET) radiotracer, which is suitable for imaging of the stress signal non-receptor tyrosine kinase c-abl, and its use in in vivo diagnosis, pre-clinical and clinical imaging, patient stratification based on the c-abl mutation status, and assessment of response to treatment. The present disclosure also relates to the use of an [¹⁸F]-labeled imidazopyridine derivative as a PET radiotracer. The present disclosure also provides a method for radiosynthesizing an [¹⁸F]-labeled imidazopyridine derivative.

The present disclosure relates to [18F]-labeled imidazopyridine derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in in vivo diagnosis, preclinical and clinical imaging, patient stratification on the basis of mutational status of c-abl and assessing response to therapeutic treatments. The present disclosure further relates to the use of [18F]-labeled imidazopyridine derivatives as PET radiotracers. The disclosure also provides a process for the radiosynthesis of [18F]-labeled imidazopyridinederivatives.

According to various aspects of the present disclosure, the present disclosure relates to an automated process for the radiosynthesis of [18F]FSPG, a positron emission tracer. The automated optimization process of the present invention enables the centralized and large-scale production of [18F]FSPG for commercial use.

The disclosure provides for methods, including automated methods, of radio synthesizing certain 2'-deoxy-2'-[18F]fluoro-5-substituted-1-β-D-arabinofuranosyl-uracil and related compounds such as, for example, 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyl-uracil ([18F]FMAU).

According to various aspects of this disclosure, the present disclosure relates to an automated process for the radiosynthesis of [18F]FSPG, a positron emission tracer. The automated optimized process of the present invention enables the centralized and large-scale production of [18F]FSPG for commercial use.

The present invention relates to an automated radiosynthesis device adapted for enhanced automatic disconnection of a disposable kit once a radiosynthesis has been carried out. The automated radiosynthesis device of the invention therefore reduces the time to remove the disposable kit from the radiosynthesis device and reduces radiation exposure to the operator.

The disclosure provides for methods, including automated methods, of radio synthesizing certain 2'-deoxy-2'-[18F]fluoro-5-substituted-1-β-D-arabinofuranosyl-uracil and related compounds such as, for example, 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyl-uracil ([18F]FMAU).